Literature DB >> 26137018

Expression and prognostic significance of TAp73 and ΔNp73 in FIGO stage I-II cervical squamous cell carcinoma.

Weipei Zhu1, Xiaohong Pan1, Zhujuan Yang1, Pengfei Xing2, Yongshen Zhang3, Feng Li3, Xueguan Lu2.   

Abstract

The purpose of the present study was to investigate the expression of TAp73 and ΔNp73 in cervical squamous cancer cells, and to evaluate the prognostic significance of TAp73 and ΔNp73 expression in patients with International Federation of Gynecology and Obstetrics (FIGO) stage I-II cervical squamous cell carcinoma (SCC). The immunohistochemical expression of TAp73 and ΔNp73 was evaluated in 59 FIGO stage I-II cervical SCC tumor samples. Correlations with clinicopathological characteristics were determined by χ2 test. The prognostic impact of TAp73 and ΔNp73 expression with regard to overall survival (OS) was determined by the Kaplan-Meier method. High TAp73 and ΔNp73 expression was detected in 79.7% (47/59) and 76.3% (45/59) of patients, respectively. The expression of TAp73 and ΔNp73 was not associated with age, FIGO stage, pathological differentiation or lymph node metastasis. The 3-year OS rates associated with low and high TAp73 expression were 75.0 and 83.0%, respectively (χ2=0.33; P=0.568), whereas those associated with low and high ΔNp73 expression were 100.0 and 75.6%, respectively (χ2=3.90; P=0.048). High expression levels of TAp73 and ΔNp73 were frequently observed in the cervical squamous cancer cells. Overall, high expression levels of ΔNp73 may indicate an unfavorable prognosis in patients with early-stage cervical SCC.

Entities:  

Keywords:  cervical cancer; p73; prognosis

Year:  2015        PMID: 26137018      PMCID: PMC4467234          DOI: 10.3892/ol.2015.3052

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  21 in total

1.  The two faces of p73.

Authors:  T J Grob; M F Fey; A Tobler
Journal:  Cell Death Differ       Date:  2002-03       Impact factor: 15.828

2.  Prognostic model for survival in patients with early stage cervical cancer.

Authors:  Petra Biewenga; Jacobus van der Velden; Ben Willem J Mol; Lukas J A Stalpers; Marten S Schilthuis; Jan Willem van der Steeg; Matthé P M Burger; Marrije R Buist
Journal:  Cancer       Date:  2010-10-04       Impact factor: 6.860

3.  Epithelial-mesenchymal transition in cervical carcinoma.

Authors:  Mei-Yi Lee; Meng-Ru Shen
Journal:  Am J Transl Res       Date:  2012-01-01       Impact factor: 4.060

4.  Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers.

Authors:  Kerstin Becker; Petr Pancoska; Nicole Concin; Kelly Vanden Heuvel; Neda Slade; Margaret Fischer; Eva Chalas; Ute M Moll
Journal:  Int J Oncol       Date:  2006-10       Impact factor: 5.650

Review 5.  Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature.

Authors:  Gerda Hofstetter; Astrid Berger; Martina Chamson; Elisabeth Müller-Holzner; Daniel Reimer; Hanno Ulmer; Hidetaka Uramoto; Christian Marth; Alain G Zeimet; A G Zeimet; Alain G Zeimet; Robert Zeillinger; Nicole Concin
Journal:  Int J Gynecol Pathol       Date:  2011-11       Impact factor: 2.762

6.  The Role of p63 and p73 in tumor formation and progression: coming of age toward clinical usefulness. Commentary re: F. Koga et al., Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin. Cancer Res., 9: 5501-5507, 2003, and P. Puig et al., p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder Cancer. Clin. Cancer Res., 9: 5642-5651, 2003.

Authors:  Ute M Moll
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

Review 7.  p53 Family isoforms.

Authors:  Jean-Christophe Bourdon
Journal:  Curr Pharm Biotechnol       Date:  2007-12       Impact factor: 2.837

8.  Validation of existing prognostic models in patients with early-stage cervical cancer.

Authors:  Petra Biewenga; Jacobus van der Velden; Ben Willem J Mol; Lukas J A Stalpers; Marten S Schilthuis; Jan Willem van der Steeg; Matthé P M Burger; Marrije R Buist
Journal:  Gynecol Oncol       Date:  2009-09-08       Impact factor: 5.482

Review 9.  p73: Friend or foe in tumorigenesis.

Authors:  Gerry Melino; Vincenzo De Laurenzi; Karen H Vousden
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

10.  Delta N-p73: the enemy within.

Authors:  P Salomoni; M J S Dyer
Journal:  Cell Death Differ       Date:  2005-12       Impact factor: 15.828

View more
  4 in total

Review 1.  Clinical implications of the deregulated TP73 isoforms expression in cancer.

Authors:  N Rodríguez; A Peláez; R Barderas; G Domínguez
Journal:  Clin Transl Oncol       Date:  2017-12-11       Impact factor: 3.405

Review 2.  Splicing Genomics Events in Cervical Cancer: Insights for Phenotypic Stratification and Biomarker Potency.

Authors:  Flavia Zita Francies; Sheynaz Bassa; Aristotelis Chatziioannou; Andreas Martin Kaufmann; Zodwa Dlamini
Journal:  Genes (Basel)       Date:  2021-01-20       Impact factor: 4.096

3.  The expression of mouse double minute 2 homolog and P73 had no correlation with growth arrest DNA damage-inducible gene 45α in patients with non-small-cell lung carcinoma: A STROBE-compliant study.

Authors:  Bo Wang; Chaoyang Liang; Huifeng Liu; Jixing Lin; Bailin Wang; Kaijie Fan; Zhipeng Ren; Bin Wang; Tong Li; Kang Qi; Xiaodong Tian
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

4.  Image-Based Network Analysis of DNp73 Expression by Immunohistochemistry in Rectal Cancer Patients.

Authors:  Tuan D Pham; Chuanwen Fan; Daniella Pfeifer; Hong Zhang; Xiao-Feng Sun
Journal:  Front Physiol       Date:  2020-01-08       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.